BioNTech (NASDAQ:BNTX) has completed the building of its first plasmid DNA manufacturing facility in Marburg, Germany.
Plasmid DNA are the building blocks for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies.
The new plant will be used in support of product candidates and commercial products in cancer and infectious diseases.
The facility actually covers two areas: clinical and commercial plasmid DNA. The clinical side is already running, while the commercial one should be operational by the end of the year.